Prescription Ecstasy and Other Pipe Dreams: An Update on Psychedelic Research

RU Sirius interviews Jag Davies of MAPS about developments in psychedelic research:

RU: So a while back, MAPS got approval for a study in MDMA-assisted psychotherapy. Where are we at with that?

JAG: It’s almost over. They’ve treated 15 out of 20 patients. It’s very slow. There are lots of pre-conditions for the study because it’s such a controversial substance. But the results are ridiculous. Their CAPS score—(CAPS is the Clinician Administered PTSD [post-traumatic stress disorder] Scale) is about five times higher than in treating chronic treatment-resistant patients with Zoloft. It’s very likely that we’re going to be able to go on to do our next set up studies—Phase III studies. And there are a whole other slew of studies that are sort of copying this one that we’re doing in a bunch of other places like Switzerland, and Israel, just to be sure.

More at link.